OncoTherapy Science, Inc.
4564.T · JPX
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Market Cap | ¥7,312 | ¥4,256 | ¥9,054 | ¥12,935 |
| - Cash | ¥834 | ¥528 | ¥1,118 | ¥1,837 |
| + Debt | ¥51 | ¥107 | ¥0 | ¥0 |
| Enterprise Value | ¥6,529 | ¥3,835 | ¥7,937 | ¥11,098 |
| Revenue | ¥750 | ¥610 | ¥1,135 | ¥1,154 |
| % Growth | 22.9% | -46.2% | -1.6% | – |
| Gross Profit | -¥13 | -¥178 | ¥42 | ¥114 |
| % Margin | -1.7% | -29.1% | 3.7% | 9.9% |
| EBITDA | -¥812 | -¥1,285 | -¥1,091 | -¥2,037 |
| % Margin | -108.2% | -210.7% | -96.1% | -176.6% |
| Net Income | -¥815 | -¥1,288 | -¥1,119 | -¥2,572 |
| % Margin | -108.7% | -211.1% | -98.6% | -222.9% |
| EPS Diluted | -3.12 | -6.05 | -5.81 | -13.72 |
| % Growth | 48.4% | -4.1% | 57.7% | – |
| Operating Cash Flow | -¥815 | -¥1,228 | -¥795 | -¥2,073 |
| Capital Expenditures | -¥0 | -¥3 | -¥5 | -¥457 |
| Free Cash Flow | -¥815 | -¥1,231 | -¥800 | -¥2,530 |